Literature DB >> 11762335

Chemotherapy and biotherapy in the treatment of neuroendocrine tumours.

K Oberg1.   

Abstract

The medical treatment of neuroendocrine GEP tumours must be based on the growth properties of the tumour. Medical treatment includes chemotherapy, somatostatin analogues and alpha interferons. Chemotherapy has been particularly active in patients with high proliferating neuroendocrine tumours such as endocrine pancreatic tumours and lung carcinoids. Streptozotocin-based combinations including 5-flourouracil and doxorubicin have generated partial remissions in 40%-60% of the patients giving a median survival of about two years in patients with advanced disease. Cisplatinum plus etoposide have demonstrated significant antitumour effects in anaplastic endocrine pancreatic tumours and lung carcinoids. However, in low proliferating tumours such as classical midgut carcinoids the response rates with the same combinations of cytotoxic agents have only generated short lasting responses in less than 10% of patients. In these patients, biological treatment has been of benefit. Alpha interferon at doses of 3-9 million units three to seven times per week subcutaneously, has given biochemical response rates of 50% and significant tumour reduction in about 15% of patients with long duration, up to three years. Somatostatin analogues have been widely used in the treatment of neuroendocrine gut and pancreatic tumours. The currently available somatostatin analogues particularly bind somatostatin receptor 2 and 5 and with low affinity also receptor subtype 3. Octreotide is registered in most countries for the treatment of patients with carcinoid syndrome and also VIP and glucagon producing tumours. Regular octreotide at standard doses of 100-300 microg/day gives symptomatic responses in a medium of 60% of patients and biochemical responses in up to 70% of patients. Significant tumour responses are rare, less than 5%. Long-acting formulations of somatostatin analogues have been of significant benefit for the patients with similar response rates as for regular formulations. The quality of life has been significantly improved by using the long-acting formulations.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11762335     DOI: 10.1093/annonc/12.suppl_2.s111

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  30 in total

1.  A pilot phase II study of valproic acid for treatment of low-grade neuroendocrine carcinoma.

Authors:  Tabraiz A Mohammed; Kyle D Holen; Renata Jaskula-Sztul; Daniel Mulkerin; Sam J Lubner; William R Schelman; Jens Eickhoff; Herbert Chen; Noelle K Loconte
Journal:  Oncologist       Date:  2011-05-31

Review 2.  [Liver metastases. Diagnosis and therapy].

Authors:  R Konopke; H D Saeger
Journal:  Chirurg       Date:  2003-09       Impact factor: 0.955

3.  Surgical treatment of pancreatic endocrine tumours in Italy: results of a prospective multicentre study of 262 cases.

Authors:  Alessandro Zerbi; Vanessa Capitanio; Letizia Boninsegna; Claudio Pasquali; Guido Rindi; Gianfranco Delle Fave; Marco Del Chiaro; Riccardo Casadei; Massimo Falconi
Journal:  Langenbecks Arch Surg       Date:  2010-09-21       Impact factor: 3.445

Review 4.  Therapeutic and palliative options for diffuse neuroendocrine metastatic disease.

Authors:  Kyle Holen
Journal:  J Gastrointest Surg       Date:  2006-03       Impact factor: 3.452

5.  Poorly differentiated small cell neuroendocrine carcinoma localized in three different endocrine glands: response to chemotherapy and octreotide LAR.

Authors:  L Tauchmanovà; M Pensabene; I Capuano; I Spagnoletti; P Zeppa; S Del Vecchio; M Mainenti; G De Rosa; A Colao; A Contegiacomo
Journal:  J Endocrinol Invest       Date:  2005-04       Impact factor: 4.256

Review 6.  Treatment of gastrointestinal neuroendocrine tumors with inhibitors of growth factor receptors and their signaling pathways: recent advances and future perspectives.

Authors:  Michael Höpfner; Detlef Schuppan; Hans Scherübl
Journal:  World J Gastroenterol       Date:  2008-04-28       Impact factor: 5.742

7.  Surgical resection and multidisciplinary care for primary and metastatic pancreatic islet cell carcinomas.

Authors:  Shaun McKenzie; Wendy Lee; Avo Artinyan; Brian Mailey; Alessio Pigazzi; Joshua Ellenhorn; Joseph Kim
Journal:  J Gastrointest Surg       Date:  2010-05-18       Impact factor: 3.452

Review 8.  Evolution of the restorative proctocolectomy and its effects on gastrointestinal hormones.

Authors:  Amosy E M'Koma; Paul E Wise; Roberta L Muldoon; David A Schwartz; Mary K Washington; Alan J Herline
Journal:  Int J Colorectal Dis       Date:  2007-06-19       Impact factor: 2.571

9.  Amelioration of symptoms and reduction of VIP levels after hepatic artery chemoembolization in a patient with sandostatin resistant VIPoma.

Authors:  Walid Shaib; Kisha Mitchell; M Wasif Saif
Journal:  Yale J Biol Med       Date:  2010-03

10.  Neuroendocrine Tumors of the Pancreas.

Authors:  James M. McLoughlin; Joseph A. Kuhn; Jeffrey T. Lamont
Journal:  Curr Treat Options Gastroenterol       Date:  2004-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.